STERIS plc (NYSE:STE – Get Free Report) VP John Adam Zangerle sold 1,419 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $209.28, for a total value of $296,968.32. Following the completion of the transaction, the vice president directly owned 35,259 shares in the company, valued at approximately $7,379,003.52. The trade was a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
STERIS Stock Performance
Shares of NYSE STE traded up $0.71 during trading on Tuesday, reaching $206.64. The stock had a trading volume of 859,012 shares, compared to its average volume of 795,812. STERIS plc has a one year low of $195.14 and a one year high of $269.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. The stock has a market cap of $20.14 billion, a PE ratio of 26.06 and a beta of 0.93. The firm’s 50 day moving average price is $215.83 and its two-hundred day moving average price is $236.76.
STERIS (NYSE:STE – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The company’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, research analysts forecast that STERIS plc will post 11.18 earnings per share for the current fiscal year.
STERIS Announces Dividend
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the company. Weiss Ratings lowered STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. KeyCorp cut their price target on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $270.00 price target on shares of STERIS in a report on Thursday, May 21st. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $278.00.
View Our Latest Stock Report on STE
Institutional Investors Weigh In On STERIS
A number of institutional investors have recently made changes to their positions in STE. Jones Financial Companies Lllp boosted its holdings in shares of STERIS by 46.1% during the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after acquiring an additional 349 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of STERIS by 32.3% during the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after acquiring an additional 59,264 shares during the period. Empowered Funds LLC boosted its holdings in shares of STERIS by 16.1% during the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after acquiring an additional 319 shares during the period. Woodline Partners LP boosted its stake in shares of STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after buying an additional 2,372 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after buying an additional 5,803 shares during the period. Institutional investors own 94.69% of the company’s stock.
STERIS Company Profile
STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.
Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.
Read More
- Five stocks we like better than STERIS
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
